Scopus BioPharma Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2019 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Scopus BioPharma Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2022.
  • Scopus BioPharma Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $12.7M, a 47.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $12.7M +$4.12M +47.7% Dec 31, 2022 10-K 2023-04-14
Q4 2021 $8.63M +$5.67M +191% Dec 31, 2021 10-K 2023-04-14
Q4 2020 $2.96M +$1.77M +149% Dec 31, 2020 10-K 2022-04-15
Q4 2019 $1.19M Dec 31, 2019 10-K 2021-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.